GCM
Gladius Capital Management Portfolio holdings
AUM
$63.8M
This Quarter Return
+1.19%
1 Year Return
+3.49%
3 Year Return
+10.82%
5 Year Return
+16.08%
10 Year Return
+49.7%
AUM
$325M
AUM Growth
+$325M
(+2.9%)
Cap. Flow
-$2.14M
Cap. Flow
% of AUM
-0.66%
Top 10 Holdings %
Top 10 Hldgs %
80.31%
Holding
367
New
58
Increased
82
Reduced
141
Closed
69
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$91.5M |
| 2 |
Invesco QQQ Trust
QQQ
|
$17.1M |
| 3 |
JPMorgan Chase
JPM
|
$6.07M |
| 4 |
Bank of America
BAC
|
$4.11M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$4.05M |
Top Sells
| 1 |
Apple
AAPL
|
$30.1M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
$28.1M |
| 3 |
UnitedHealth
UNH
|
$22.5M |
| 4 |
NVIDIA
NVDA
|
$13.6M |
| 5 |
Walmart
WMT
|
$11M |
Sector Composition
| 1 | Financials | 6.83% |
| 2 | Healthcare | 5.61% |
| 3 | Consumer Staples | 3.91% |
| 4 | Technology | 3.24% |
| 5 | Consumer Discretionary | 2.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Zynex
ZYXI
$45.1M
| $30.9K | ﹤0.01% |
2,577
-206
| -7% | -$2.47K |
|
202
Cullinan Oncology
CGEM
$456M
| $30.5K | ﹤0.01% |
2,978
-16
| -0.5% | -$164 |
|
|
EGRX
203
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $29.8K | ﹤0.01% |
1,052
-2
| -0.2% | -$57 |
|
204
Cross Country Healthcare
CCRN
$420M
| $29.7K | ﹤0.01% |
1,331
+260
| +24% | +$5.8K |
|
205
Collegium Pharmaceutical
COLL
$1.25B
| $29.6K | ﹤0.01% |
1,235
-478
| -28% | -$11.5K |
|
206
Organogenesis Holdings
ORGO
$629M
| $29.5K | ﹤0.01% |
13,833
+120
| +0.9% | +$256 |
|
207
SpartanNash
SPTN
$909M
| $29.4K | ﹤0.01% |
+1,184
| New | +$29.4K |
|
208
Orthofix Medical
OFIX
$583M
| $29K | ﹤0.01% |
1,733
-285
| -14% | -$4.77K |
|
|
AEL
209
DELISTED
American Equity Investment Life Holding Company
AEL
| $28.7K | ﹤0.01% |
786
-152
| -16% | -$5.55K |
|
210
Viatris
VTRS
$12.3B
| $28.5K | ﹤0.01% |
2,960
-458
| -13% | -$4.41K |
|
211
SIGA Technologies
SIGA
$617M
| $28.3K | ﹤0.01% |
4,930
+690
| +16% | +$3.97K |
|
212
Vir Biotechnology
VIR
$765M
| $28.3K | ﹤0.01% |
1,216
-148
| -11% | -$3.44K |
|
|
AAN
213
DELISTED
The Aaron's Company, Inc.
AAN
| $28.3K | ﹤0.01% |
2,928
-3,226
| -52% | -$31.2K |
|
214
Organon & Co
OGN
$2.56B
| $28.1K | ﹤0.01% |
1,195
-229
| -16% | -$5.38K |
|
|
EQRX
215
DELISTED
EQRx, Inc. Common Stock
EQRX
| $28.1K | ﹤0.01% |
+14,473
| New | +$28.1K |
|
216
Emergent Biosolutions
EBS
$418M
| $28.1K | ﹤0.01% |
2,709
-404
| -13% | -$4.19K |
|
|
MDRX
217
DELISTED
Veradigm Inc. Common Stock
MDRX
| $27.7K | ﹤0.01% |
+2,126
| New | +$27.7K |
|
218
TrueCar
TRUE
$183M
| $27.6K | ﹤0.01% |
12,021
-2,367
| -16% | -$5.44K |
|
219
Century Therapeutics
IPSC
$40.4M
| $26.8K | ﹤0.01% |
+7,730
| New | +$26.8K |
|
|
BCOV
220
DELISTED
Brightcove, Inc.
BCOV
| $26.5K | ﹤0.01% |
5,955
-852
| -13% | -$3.79K |
|
221
Unisys
UIS
$273M
| $26K | ﹤0.01% |
6,700
-5,328
| -44% | -$20.7K |
|
222
Lyell Immunopharma
LYEL
$220M
| $26K | ﹤0.01% |
+550
| New | +$26K |
|
223
Celularity
CELU
$61.1M
| $25.9K | ﹤0.01% |
+4,184
| New | +$25.9K |
|
224
Atea Pharmaceuticals
AVIR
$275M
| $25.8K | ﹤0.01% |
7,713
-200
| -3% | -$670 |
|
225
Arteris
AIP
$377M
| $25.7K | ﹤0.01% |
+6,066
| New | +$25.7K |
|